Influenza or flu vaccines provide protection from the true influenza. The infection affects the upper airways. A distinction is made between vaccines against seasonal influenza, which occurs every winter, and non-seasonal influenza vaccines, which are used in the event of impending influenza pandemics (zoonotic pre-pandemic vaccines and pandemic vaccines).
| Name | Description | Marketing Authorisation Holder | License Number | License Date | Further Information |
|---|---|---|---|---|---|
Efluelda 2025/2026 |
Trivalenter Influenza-Spaltimpfstoff (Virusimpfstoff, inaktiviert, 60 Mikrogramm HA/Stamm) Verwendung ab einem Lebensalter von 60 Jahren / Use from 60 years of age onwards |
Sanofi Winthrop Industrie |
PEI.H.12205.01.1 | 14.11.2024 |
Hersteller: |
Efluelda Tetra 2025/2026 |
Influenza-Spaltimpfstoff (Virusimpfstoff, inaktiviert, 60 Mikrogramm HA/Stamm) Verwendung ab einem Lebensalter von 60 Jahren / Use from 60 years of age onwards |
Sanofi Winthrop Industrie |
PEI.H.12011.01.1 | 05.05.2020 |
Hersteller: Wird derzeit in Deutschland nicht vermarktet / Not currently marketed in Germany |
Fluad 2025/2026 |
Trivalenter Influenza-Untereinheiten-Impfstoff aus Oberflächenantigen Verwendung ab einem Lebensalter von 50 Jahren / Use from 50 years of age onwards |
Seqirus Netherlands B.V. |
EU/1/24/1878 | 19.11.2024 |
Hersteller: |
Flucelvax 2025/2026 |
Trivalenter Influenza-Untereinheiten-Impfstoff aus Oberflächenantigen Verwendung ab einem Lebensalter von 6 Monaten / Use from an age of 6 months |
Seqirus Netherlands B.V. |
EU/1/24/1879 | 26.11.2024 |
Hersteller: |
Fluenz 2025/2026 |
Influenza-Impfstoff Verwendung ab einem Lebensalter von 2 Jahren bis einschließlich 17 Jahren / Use from an age of 2 years up to and including 17 years |
AstraZeneca AB, SE-151 85 Södertälje, Schweden |
EU/1/24/1816 | 03.06.2024 |
Hersteller: |
Influsplit 2025/2026 |
Trivalenter Influenza-Spaltimpfstoff (Virusimpfstoff, inaktiviert) intramuskulär Injektionssuspension in einer Fertigspritze Verwendung ab einem Lebensalter von 6 Monaten / Use from an age of 6 months |
GlaxoSmithKline GmbH & Co. KG, |
PEI.H.12218.01.1 | 27.02.2025 |
Hersteller: |
Influsplit Tetra 2025/2026 |
Influenza-Spaltimpfstoff Verwendung ab einem Lebensalter von 6 Monaten / Use from an age of 6 months |
GlaxoSmithKline GmbH & Co. KG, |
PEI.H.11629.01.1 | 04.03.2013 |
Hersteller: Wird derzeit in Deutschland nicht vermarktet / Not currently marketed in Germany |
Influvac 2025/2026 |
Influenza-Untereinheiten-Impfstoff aus Oberflächenantigen Verwendung ab einem Lebensalter von 6 Monaten / Use from an age of 6 months |
Viatris Healthcare GmbH, |
PEI.H.12203.01.1 | 24.05.2024 |
Hersteller: |
Influvac Tetra 2025/2026 |
Influenza-Untereinheiten-Impfstoff aus Oberflächenantigen Verwendung ab einem Lebensalter von 6 Monaten / Use from an age of 6 months |
Viatris Healthcare GmbH, |
PEI.H.11881.01.1 | 31.07.2017 |
Hersteller: Wird derzeit in Deutschland nicht vermarktet / Not currently marketed in Germany |
Vaxigrip 2025/2026 |
Trivalenter Influenza-Spaltimpfstoff (Virusimpfstoff, inaktiviert) intramuskulär oder subkutan Injektionssuspension in einer Fertigspritze Verwendung ab einem Lebensalter von 6 Monaten / Use from an age of 6 months |
Sanofi Winthrop Industrie |
PEI.H.12206.01.1 | 25.11.2024 |
Hersteller: |
Vaxigrip Tetra 2025/2026 |
Influenza-Spaltimpfstoff (Virusimpfstoff, inaktiviert) intramuskulär oder subkutan Injektionssuspension in einer Fertigspritze Verwendung ab einem Lebensalter von 6 Monaten / Use from an age of 6 months |
Sanofi Winthrop Industrie |
PEI.H.11808.01.1 | 14.07.2016 |
Hersteller: Wird derzeit in Deutschland nicht vermarktet / Not currently marketed in Germany |
Xanaflu 2025/2026 |
Influenza-Untereinheiten-Impfstoff aus Oberflächenantigen Verwendung ab einem Lebensalter von 6 Monaten / Use from an age of 6 months |
Viatris Healthcare GmbH, |
PEI.H.12204.01.1 | 22.05.2024 |
Hersteller: |
Xanaflu Tetra 2025/2026 |
Influenza-Untereinheiten-Impfstoff aus Oberflächenantigen Verwendung ab einem Lebensalter von 6 Monaten / Use from an age of 6 months |
Viatris Healthcare GmbH, |
PEI.H.11882.01.1 | 31.07.2017 |
Hersteller: Wird derzeit in Deutschland nicht vermarktet / Not currently marketed in Germany |
| Name | Description | Marketing Authorisation Holder | License Number | License Date | Further Information |
|---|---|---|---|---|---|
Fluad Tetra |
Influenza-Untereinheiten-Impfstoff aus Oberflächenantigen Verwendung ab einem Lebensalter von 50 Jahren / Use from 50 years of age onwards |
Seqirus Netherlands B.V. |
EU/1/20/1433 | 20.05.2020 |
Hersteller: |
Flucelvax Tetra |
Influenza-Untereinheiten-Impfstoff aus Oberflächenantigen Verwendung ab einem Lebensalter von 6 Monaten / Use from an age of 6 months |
Seqirus Netherlands B.V. |
EU/1/18/1326 | 12.12.2018 |
Hersteller: |
Fluenz Tetra |
Influenza-Impfstoff Verwendung ab einem Lebensalter von 2 Jahren bis einschließlich 17 Jahren / Use from an age of 2 years up to and including 17 years |
AstraZeneca AB, SE-151 85 Södertälje, Schweden |
EU/1/13/887 | 04.12.2013 |
Hersteller: |
Supemtek Tetra |
Influenza-Impfstoff (rekombinant, hergestellt in Zellkultur) Verwendung ab einem Lebensalter von 9 Jahren / Use from 9 years of age onwards |
Sanofi Winthrop Industrie |
EU/1/20/1484 | 16.11.2020 |
Hersteller: |
Vaxigrip Tetra |
Influenza-Spaltimpfstoff (Virusimpfstoff, inaktiviert) intramuskulär oder subkutan Injektionssuspension in einer Durchstechflasche zur Mehrfachentnahme Verwendung ab einem Lebensalter von 6 Monaten / Use from an age of 6 months |
Sanofi Winthrop Industrie |
PEI.H.11808.02.1 | 29.01.2020 | Hersteller: |
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 534 in BAnz AT 29.10.2025 B5.
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
Updated: 21.07.2025
Season 2025/2026
Stand/ as of: 02.11.2025 / 2 November 2025
Source: Paul-Ehrlich-Institut
| Date | Calendar- week | Number of Doses of Vaccines (total Number) |
|---|---|---|
| 2 November 2025 | 44 | aprox. 18,5 Million |
| 26 October 2025 | 43 | aprox. 18,5 Million |
| 19 October 2025 | 42 | aprox. 18,5 Million |
| 12 October 2025 | 41 | aprox. 18,5 Million |
| 5 October 2025 | 40 | aprox. 18,3 Million |
| 28 September 2025 | 39 | aprox. 18,3 Million |
| 21 September 2025 | 38 | aprox. 17,6 Million |
| 14 September 2025 | 37 | aprox. 17,6 Million |
| 7 September 2025 | 36 | aprox. 16,2 Million |
| 31 August 2025 | 35 | aprox. 16,1 Million |
| 24 August 2025 | 34 | aprox. 14,7 Million |
| 17 August 2025 | 33 | aprox. 9.3 Million |
| 10 August 2025 | 32 | aprox. 7.4 Million |
Updated: 03.11.2025
The influenza vaccine for the 2025/2026 season is composed of the antigens of globally circulating variants of viruses according to the recommendations of the WHO and the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA).
This composition differs from that of the 2024/2025 season.
| WHO Recommendations* for the northern hemisphere | Suitable strains according to the recommendations of the EMA |
|---|---|
| A/Victoria/4897/2022 (H1N1)pdm09-like virus |
|
| A/Croatia/10136RV/2023 (H3N2)-like virus |
|
| B/Austria/1359417/2021 (B/Victoria lineage)-like virus |
|
| WHO Recommendations* for the northern hemisphere | Suitable strains according to the recommendations of the EMA |
|---|---|
| A/Wisconsin/67/2022 (H1N1)pdm09-like virus |
|
| A/District of Columbia/27/2023 (H3N2)-like virus |
|
| B/Austria/1359417/2021 (B/Victoria lineage)-like virus |
|
| WHO Recommendations* for the northern hemisphere | Suitable strains according to the recommendations of the EMA |
|---|---|
| A/Victoria/4897/2022 (H1N1)pdm09-like virus | Virus MEDI 369815, which is derived from A/Norway/31694/2022 |
| A/Croatia/10136RV/2023 (H3N2)-like virus | Virus MEDI 392611, which is derived from A/Perth/722/2024 |
| B/Austria/1359417/2021 (B/Victoria lineage)-like virus | Virus MEDI 355292, which is derived from B/Austria/1359417/2021 |
For the production of inactivated quadrivalent vaccines containing two influenza B virus strains, a B/Phuket/3073/2013 (B/Yamagata lineage)-like strain is considered suitable for the 2025/2026 season in addition to the strains mentioned above.
| WHO Recommendations* for the northern hemisphere | Suitable strains according to the recommendations of the EMA |
|---|---|
| B/Phuket/3073/2013 (B/Yamagata lineage)-like virus |
|
| WHO Recommendations* for the northern hemisphere | Suitable strains according to the recommendations of the EMA |
|---|---|
| B/Phuket/3073/2013 (B/Yamagata lineage)-like virus |
|
* A and B denote the virus types, the place name refers to the place of virus isolation; the first digit indicates the number of the isolated strain, the second refers to the year of isolation. H and N are the two most important proteins in the virus envelope hemagglutinin and neuraminidase, the number behind them indicates the hemagglutinin and neuraminidase subtype.
Updated: 15.04.2025
Influenza or flu vaccines provide protection from the true influenza. The infection affects the upper airways. A distinction is made between vaccines against seasonal influenza, which occurs every winter, and non-seasonal influenza vaccines, which are used in the event of impending influenza pandemics (zoonotic pre-pandemic vaccines and pandemic vaccines).
| Name | Description | Marketing Authorisation Holder | Kind of Vaccine | License Number | License Date | Further Information |
|---|---|---|---|---|---|---|
|
Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) |
Pandemischer Influenza-Impfstoff (H5N1) |
GlaxoSmithKline Biologicals S.A., Belgien |
Mono | EU/1/09/578/001 | 19.10.2009 |
Wird derzeit in Deutschland nicht vermarktet |
|
Aflunov |
Zoonotischer Influenza-Impfstoff (H5N1) |
Seqirus S.r.l. |
Mono | EU/1/10/658 | 29.11.2010 | |
Celldemic |
Zoonotischer Influenza-Impfstoff (H5N1) (Oberflächenantigen, inaktiviert, adjuvantiert, hergestellt in Zellkulturen) |
Seqirus Netherlands B.V. |
Mono | EU/1/24/1806 | 22.04.2024 | |
|
Foclivia |
Pandemischer Influenza-Impfstoff (H5N1) (gereinigtes Oberflächenantigen) |
Seqirus S.r.l., Italien |
Mono | EU/1/09/577/001-004 | 19.10.2009 | |
Incellipan |
Pandemischer Influenza-Impfstoff (H5N1) (Oberflächenantigen, inaktiviert, adjuvantiert, hergestellt in Zellkulturen) |
Seqirus Netherlands B.V. |
Mono | EU/1/24/1807 | 22.04.2024 | |
|
Pandemic influenza vaccine H5N1 Astra Zeneca |
Pandemischer Influenza-Impfstoff (H5N1) |
AstraZeneca AB |
Mono | EU/1/16/1089 | 20.05.2016 | |
Zoonotic Influenza Vaccine Seqirus |
Zoonotischer Influenza-Impfstoff (H5N8) (Oberflächenantigen, inaktiviert, adjuvantiert) |
Seqirus S.r.l. |
Mono | EU/1/23/1761 | 10.10.2023 |
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 534 in BAnz AT 29.10.2025 B5.
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
Updated: 29.10.2025
